← Leaderboards
Swee Lay Thein
National Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Heart, Lung, And Blood Institute
Same institution · by research overlap
Others in their field
Top investigators on “Sickle Cell”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$39,292,302
- Martin H. Steinberg · Boston Medical Center$27,959,870
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,833,466
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle CellSickle Cell AnemiaSicklingErythrocytesHemoglobinAcuteOrganProtocols DocumentationOxygenSamplingPainFetal HemoglobinReportingComplicationBloodPolymerizationSeverity Of IllnessPathway InteractionsAffinityProductionSickle Cell TraitPyruvate KinaseBindingResponse
Grant awards (43)
Studies of the Natural History of Sickle Cell Disease$958,053
ZIA · FY2025 · HL · contact PI
Human Specimen Collection to Support Basic and Clinical Research$775,566
ZIA · FY2025 · HL · contact PI
Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease$684,323
ZIA · FY2025 · HL · contact PI
A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease$684,323
ZIA · FY2025 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$684,323
ZIA · FY2025 · HL · contact PI
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$456,215
ZIA · FY2025 · HL · contact PI
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease$228,108
ZIA · FY2025 · HL · contact PI
Exploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$45,622
ZIA · FY2025 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$45,622
ZIA · FY2025 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$986,035
ZIA · FY2024 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$939,081
ZIA · FY2024 · HL · contact PI
Human Specimen Collection to Support Basic and Clinical Research$845,173
ZIA · FY2024 · HL · contact PI
Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease$704,311
ZIA · FY2024 · HL · contact PI
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$469,540
ZIA · FY2024 · HL · contact PI
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease$234,770
ZIA · FY2024 · HL · contact PI
Exploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$234,770
ZIA · FY2024 · HL · contact PI
A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease$234,770
ZIA · FY2024 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$46,954
ZIA · FY2024 · HL · contact PI
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$1,480,145
ZIA · FY2023 · HL · contact PI
Exploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$986,763
ZIA · FY2023 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$986,763
ZIA · FY2023 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$986,763
ZIA · FY2023 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$493,382
ZIA · FY2023 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$1,185,563
ZIA · FY2022 · HL · contact PI
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$1,132,976
ZIA · FY2022 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$790,375
ZIA · FY2022 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$790,375
ZIA · FY2022 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$1,444,860
ZIA · FY2021 · HL · contact PI
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$1,444,860
ZIA · FY2021 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$825,634
ZIA · FY2021 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$412,817
ZIA · FY2021 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$954,373
ZIA · FY2020 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$954,373
ZIA · FY2020 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$954,373
ZIA · FY2020 · HL · contact PI
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease$954,373
ZIA · FY2020 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$1,023,525
ZIA · FY2019 · HL · contact PI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$1,023,525
ZIA · FY2019 · HL · contact PI
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$1,023,525
ZIA · FY2019 · HL · contact PI
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease$1,023,525
ZIA · FY2019 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$2,494,416
ZIA · FY2018 · HL · contact PI
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease$2,494,416
ZIA · FY2018 · HL · contact PI
Studies of the Natural History of Sickle Cell Disease$1,916,791
ZIA · FY2017 · HL · contact PI
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease$1,916,791
ZIA · FY2017 · HL · contact PI